Encrypted login | home

Program Information

Statistical Analysis of In-Vivo Measurements of Doses at Various Body Sites of Patients Treated with Total Skin Electron Irradiation Therapy

C Wang

C Wang1*, H Wang2 , Y Liu3 , R Tailor4 , S Tung5 , P Chi6 , B Dabaja7 , C Pinnix8 , (1) MD Anderson Cancer Center, Houston, TX, (2) UT MD Anderson Cancer Center, Houston, TX, (3) Memorial Sloan Kettering Cancer Center, New York, NY, (4) UT MD Anderson Cancer Center, Houston, TX, (5) UT MD Anderson Cancer Center, Houston, TX, (6) M.D. Anderson Cancer Center, Houston, TX, (7) M.D.Anderson Cancer Center, Houston, Texas, (8) M.D.Anderson Cancer Center, Houston, Texas


SU-J-CAMPUS-TT-2 (Sunday, July 30, 2017) 4:00 PM - 5:00 PM Room: Therapy ePoster Theater

Purpose: Total skin electron beam (TSEB) irradiation therapy has been employed to treat Mycosis Fungoides. In-vivo measurement of dose at various body sites is needed to determine boost doses to areas that are not fully exposed to the irradiation beam. The purpose of this study is to analyze our multi-year Thermoluminescent Dosimetry (TLD) measurement results and provide a reference to TSEB treatment.

Methods: From 2007 to 2016, we have >150 patients treated with a modified Stanford 6-field TSEB technique using 9 MeV electron beam of Linac. Results of TLD measurements at 25 body sites of these patients were analyzed in terms of mean dose and standard deviation. The results were also compared among different gender, age, and body mass index (BMI) groups. Guidelines can be derived to minimize the site numbers of measurement.

Results: Body sites that have full exposure to radiation beams are consistent with prescription dose. Umbilicus, sternum, and back are all within 4% of prescribed dose. While other sites deviates from prescribed dose in different degrees, some sites are consistent and others are found closely related to factors such as gender, age, and patient’s BMI. For example, dose in the breast fold is 93% for men and 48% for women. Dose at groins is 89% for patient with BMI<=25, and 55% for patients with BMI>30. For patients of age above or below 50, doses to breast folds, buttock folds and lower abdomen also differ by more than 10%. For several measurement sites other than prescription sites which had consistent doses, TLD placements are optional.

Conclusion: Statistical results of in-vivo TLD measurement of 25 body sites over 150 TSEB patients were presented and analyzed according to gender, age, and patients’ BMI. The data collected from a large number of patients serves as a reliable reference to TSEB treatment.

Contact Email: